AbbVie Acquires Stemcentrx for $10,200,000,000

  • Feed Type
  • Date
    4/28/2016
  • Company Name
    Stemcentrx
  • Mailing Address
    450 E Jamie Ct. South San Francisco, CA 94080 USA
  • Company Description
    Our mission is to develop therapies that cure and significantly improve survival for cancer patients. We are pioneering new approaches to eliminate cancer stem cells, which initiate and perpetuate tumors.
  • Website
    http://www.stemcentrx.com
  • Transaction Type
    M&A
  • Transaction Amount
    $10,200,000,000
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    AbbVie will acquire Stemcentrx for approximately $5.8 billion in cash and stock. AbbVie will pay approximately $2.0 billion of the transaction value in cash and fund the remaining portion with stock. In addition, Stemcentrx investors are eligible to receive up to $4 billion in cash for additional, success-based milestone payments for the achievement of certain regulatory and clinical developments.

Trending on Xconomy